Chapter 30: Pain Assessment & Management in Children

Effective pain management in pediatric patients requires a multidimensional approach that balances clinical assessment with specialized pharmacological and non-pharmacological interventions. This chapter emphasizes that pain is a frequent yet often undertreated occurrence in clinical settings, necessitating rigorous assessment through developmental-specific tools. For infants and children with limited communication skills, clinicians utilize behavioral measures like the FLACC scale—focusing on facial expression, leg movement, activity, cry, and consolability—or the COMFORT scale for those in critical care environments. As children mature, self-report mechanisms such as the Wong-Baker FACES rating scale or numerical rating scales become the gold standard, allowing patients to quantify their experiences. Specialized populations, including those with cognitive impairments or chronic conditions like sickle cell disease and cancer, require individualized strategies that account for long-term opioid exposure and the risk of pseudoaddiction. The pharmacological framework follows a two-step strategy, beginning with non-opioid analgesics like acetaminophen or nonsteroidal anti-inflammatory drugs (NSAIDs) for mild pain, advancing to potent opioids such as morphine for moderate to severe distress. Notably, the chapter advises against codeine use in children due to unpredictable genetic metabolism patterns. Advanced delivery methods like patient-controlled analgesia (PCA) provide older children with autonomy, while topical anesthetics like EMLA cream mitigate the trauma of needle-related procedures. Beyond medication, the integration of cognitive-behavioral therapies, including distraction, relaxation, and guided imagery, alongside complementary health practices, plays a vital role in reducing anxiety and enhancing analgesic efficacy. Nurses must also practice diligent opioid stewardship by screening for misuse risks and managing side effects like respiratory depression with reversal agents like naloxone. Addressing pain proactively is essential to prevent the "windup phenomenon," where untreated noxious stimuli lead to central sensitization and long-term neurodevelopmental consequences. Finally, the chapter outlines the complexities of procedural sedation and end-of-life care, stressing the ethical imperative of minimizing suffering through palliative sedation when necessary.